Trevi Therapeutics, Inc. Retained Earnings
Trevi Therapeutics, Inc. (TRVI) had Retained Earnings of -$360.79 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$360.79M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$343.00M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$329.80M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$321.49M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$360.79M 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$343.00M 10-Q · filed 2026-05-05 |
| 2025-12-31 | -$329.80M 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$321.49M 10-Q · filed 2025-11-13 |
| 2025-06-30 | -$309.69M 10-Q · filed 2025-08-07 |
| 2025-03-31 | -$297.38M 10-Q · filed 2025-05-08 |
| 2024-12-31 | -$287.05M 10-K · filed 2026-03-17 |
| 2024-09-30 | -$275.63M 10-Q · filed 2024-11-06 |
| 2024-06-30 | -$262.39M 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$250.04M 10-Q · filed 2024-05-07 |
| 2023-12-31 | -$239.13M 10-K · filed 2025-03-18 |
| 2023-09-30 | -$231.31M 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$223.62M 10-Q · filed 2023-08-10 |
| 2023-03-31 | -$216.47M 10-Q · filed 2023-05-11 |
| 2022-12-31 | -$210.07M 10-K · filed 2024-03-20 |
| 2022-09-30 | -$204.56M 10-Q · filed 2022-11-10 |
| 2022-06-30 | -$196.30M 10-Q · filed 2022-08-11 |
| 2022-03-31 | -$188.25M 10-Q · filed 2022-05-12 |
| 2021-12-31 | -$180.92M 10-K · filed 2023-03-16 |
| 2021-09-30 | -$172.40M 10-Q · filed 2021-11-10 |
| 2021-06-30 | -$165.14M 10-Q · filed 2021-08-12 |
| 2021-03-31 | -$155.35M 10-Q · filed 2021-05-13 |
| 2020-12-31 | -$146.98M 10-K · filed 2022-03-17 |
| 2020-09-30 | -$137.45M 10-Q · filed 2020-11-12 |
| 2020-06-30 | -$130.08M 10-Q · filed 2020-08-13 |
| 2020-03-31 | -$122.69M 10-Q · filed 2020-05-07 |
| 2019-12-31 | -$114.22M 10-K · filed 2021-03-25 |
| 2019-09-30 | -$107.68M 10-Q · filed 2019-11-14 |
| 2019-06-30 | -$100.32M 10-Q · filed 2019-08-12 |
| 2019-03-31 | -$115.48M 10-Q · filed 2019-06-14 |
| 2018-12-31 | -$109.50M 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |